Trial Profile
Phase III Randomized, Unicentric, Double-masked, Parallel Trial for the Efficacy and Tolerability of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus the Isolated Active Substances (Flancox® 400 mg And Miosan® 10 mg) in Postoperative Pain Control After Impacted Third Molar Extraction
Status:
Not yet recruiting
Phase of Trial:
Phase III
Latest Information Update: 04 Apr 2019
Price :
$35
*
At a glance
- Drugs Cyclobenzaprine (Primary) ; Etodolac (Primary)
- Indications Postoperative pain
- Focus Therapeutic Use
- Acronyms FDCETCB-III
- Sponsors Apsen Farmaceutica
- 02 May 2017 New trial record